Novel Pharmacogenomic Locus Implicated in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema

J Am Coll Cardiol. 2021 Aug 17;78(7):710-712. doi: 10.1016/j.jacc.2021.05.050.

Authors

Stuart A Scott¹, Paola Nicoletti²

Affiliations

¹ Department of Pathology, Stanford University, Stanford, California, USA; Stanford Medicine Clinical Genomics Laboratory, Stanford Health Care, Palo Alto, California, USA. Electronic address: [email protected].
² Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Sema4, Stamford, Connecticut, USA.

PMID: 34384553
DOI: 10.1016/j.jacc.2021.05.050

No abstract available

Keywords: ACE inhibitors; ADR; adverse drug reaction; angioedema; bradykinin; bradykinin receptor B2; pharmacogenomics.

Publication types

Editorial
Comment

MeSH terms

Angioedema* / chemically induced
Angioedema* / diagnosis
Angioedema* / genetics
Angiotensin-Converting Enzyme Inhibitors* / adverse effects
Humans
Pharmacogenetics

Substances

Angiotensin-Converting Enzyme Inhibitors